Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma.
Detailed molecular profiling of large B-cell lymphoma tumors provides actionable guidance for selecting between emerging advanced therapies like CAR-T cells.
This MD Anderson-based study evaluates the clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma, demonstrating that cell-of-origin, genetic subgroup, and tumor microenvironment profiling provides actionable treatment selection information. The results support integration of comprehensive molecular panels into routine LBCL diagnostic workup, particularly for CAR-T and bispecific antibody treatment planning.
What the study was
- Study design
- Retrospective clinical utility study
- Population
- Patients with large B-cell lymphoma at an academic cancer center
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Blood advances
Why it surfaced
MD Anderson group (Westin JR) demonstrating clinical utility of real-time comprehensive molecular profiling in LBCL. Supports routine molecular panel integration for LBCL treatment selection including CAR-T eligibility. Blood Advances.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.